论文部分内容阅读
目的：了解普伐他汀降血脂疗效。方法：用最小序贯设计及期中分析法将１０２例ＩＩａ，ＩＩｂ型高脂血症病人采用双盲法分为普伐他汀组５３例，给普代他汀 １０ ｍｇ，ｐｏ， ｑｎ×８ ｗｋ；对照组 ４９例，给服外观相同的淀粉片，服法疗程相同。结果：治疗４ｗｋ与 ８ ｗｋ普伐他汀组ＴＣ下降差值分别为（１．７±０．８）ｍｍｏｌ·Ｌ－１与（２．６±０．９）ｍｍｏｌ·Ｌ－１；ＴＧ下降差值为（０．６±０．６）ｍｍｏｌ·Ｌ－１与（１．０±０．５）ｍｍｏｌ·Ｌ－１，治疗８ｗｋ后ＴＣ，ＴＧ下降差值２组组问比较Ｐ＜０．０１；普伐他汀组治疗２ ｗｋ开始ＨＤ Ｌ－Ｃ开始升高（ Ｐ＜ ０． ０５），对照组治疗 ２～ ８ ｗｋ均未见显著升高。结论：普伐他汀组有显著降低ＴＣ，ＴＧ及升高ＨＤＬＣ作用。
Objective: To understand the effect of pravastatin on lipid lowering. Methods: A total of 102 patients with type IIa and IIb hyperlipidemia were divided into pravastatin group (n = 53) and ranibutan (10 mg, po, qn × 8 wk) by minimal sequential design and mid-term analysis. Group 49 cases, to serve the same appearance of starch tablets, the same method of treatment. Results: The differences of TCs between 4wk and 8wk pravastatin groups were (1.7 ± 0.8) mmol·L-1 and (2.6 ± 0.9) mmol·L-1, respectively (0.6 ± 0.6) mmol·L-1 and (1.0 ± 0.5) mmol·L-1, respectively. After 8 weeks of treatment, the differences of TC and TG decreased between the two groups (P <0.05). 01; the HDL-C began to increase in pravastatin group 2 weeks after treatment (P <0.05), but no significant increase in control group 2 ~ 8 weeks. Conclusion: Pravastatin group can significantly reduce TC, TG and HDLC.